ABSTRACT
Mouse Mammary Tumor Virus (MMTV) causes mammary carcinoma or lymphoma in mice. An increasing body of evidence in recent years supports its involvement also in human sporadic breast cancer. It is thus of importance to develop new strategies to impair the development, growth and metastasis of MMTV-associated cancers. The signal peptide of the envelope precursor protein of this virus: MMTV-p14 (p14) is an excellent target for such strategies, due to unique characteristics distinct from its regular endoplasmic reticulum targeting function. These include cell surface expression in: murine cancer cells that harbor the virus, human breast cancer (MCF-7) cells that ectopically express p14, as well as cultured human cells derived from an invasive ductal breast carcinoma positive for MMTV sequences. These findings support its use in signal peptide-based immune targeting. Indeed, priming and boosting mice with p14 elicits a specific anti-signal peptide immune response sufficient for protective vaccination against MMTV-associated tumors. Furthermore, passive immunization using a combination of anti-p14 monoclonal antibodies or the transfer of T-cells from immunized mice (Adoptive Cell Transfer) is also therapeutically effective. With reports demonstrating involvement of MMTV in human breast cancer, we propose the immune-mediated targeting of p14 as a strategy for prevention, treatment and diagnosis of MMTV-associated cancers.
Subject(s)
Antibodies, Monoclonal/pharmacology , Breast Neoplasms/prevention & control , Carcinoma, Ductal, Breast/prevention & control , Immunization/methods , Mammary Tumor Virus, Mouse/pathogenicity , Viral Envelope Proteins/antagonists & inhibitors , Animals , Apoptosis , Breast Neoplasms/immunology , Breast Neoplasms/virology , Carcinoma, Ductal, Breast/immunology , Carcinoma, Ductal, Breast/virology , Cell Proliferation , Female , Humans , MCF-7 Cells , Mice , Mice, Inbred BALB C , Tumor Cells, Cultured , Viral Envelope Proteins/immunologyABSTRACT
The presence of dormant, microscopic cancerous lesions poses a major obstacle for the treatment of metastatic and recurrent cancers. While it is well-established that microRNAs play a major role in tumorigenesis, their involvement in tumor dormancy has yet to be fully elucidated. We established and comprehensively characterized pairs of dormant and fast-growing human osteosarcoma models. Using these pairs of mouse tumor models, we identified three novel regulators of osteosarcoma dormancy: miR-34a, miR-93, and miR-200c. This report shows that loss of these microRNAs occurs during the switch from dormant avascular into fast-growing angiogenic phenotype. We validated their downregulation in patients' tumor samples compared to normal bone, making them attractive candidates for osteosarcoma therapy. Successful delivery of miRNAs is a challenge; hence, we synthesized an aminated polyglycerol dendritic nanocarrier, dPG-NH2, and designed dPG-NH2-microRNA polyplexes to target cancer. Reconstitution of these microRNAs using dPG-NH2 polyplexes into Saos-2 and MG-63 cells, which generate fast-growing osteosarcomas, reduced the levels of their target genes, MET proto-oncogene, hypoxia-inducible factor 1α, and moesin, critical to cancer angiogenesis and cancer cells' migration. We further demonstrate that these microRNAs attenuate the angiogenic capabilities of fast-growing osteosarcomas in vitro and in vivo. Treatment with each of these microRNAs using dPG-NH2 significantly prolonged the dormancy period of fast-growing osteosarcomas in vivo. Taken together, these findings suggest that nanocarrier-mediated delivery of microRNAs involved in osteosarcoma tumor-host interactions can induce a dormant-like state.
Subject(s)
Antineoplastic Agents/chemistry , Drug Carriers/chemistry , Glycerol/chemistry , MicroRNAs/genetics , Nanostructures/chemistry , Osteosarcoma/genetics , Polymers/chemistry , Animals , Cell Line, Tumor , Drug Discovery , Humans , Mice , Mice, SCID , MicroRNAs/chemistry , Nanomedicine , Osteosarcoma/metabolism , Proto-Oncogene MasABSTRACT
To avoid genomic instability, cells have developed surveillance mechanisms such as the spindle assembly checkpoint (SAC) and the DNA damage response. ATM and MDC1 are central players of the cellular response to DNA double-strand breaks. Here, we identify a new role for these proteins in the regulation of mitotic progression and in SAC activation. MDC1 localizes at mitotic kinetochores following SAC activation in an ATM-dependent manner. ATM phosphorylates histone H2AX at mitotic kinetochores, and this phosphorylation is required for MDC1 localization at kinetochores. ATM and MDC1 are needed for kinetochore localization of the inhibitory mitotic checkpoint complex components, Mad2 and Cdc20, and for the maintenance of the mitotic checkpoint complex integrity. This probably relies on the interaction of MDC1 with the MCC. In this work, we have established that ATM and MDC1 maintain genomic stability not only by controlling the DNA damage response, but also by regulating SAC activation, providing an important link between these two essential biological processes.
Subject(s)
Ataxia Telangiectasia Mutated Proteins/metabolism , DNA Damage , Kinetochores/metabolism , M Phase Cell Cycle Checkpoints , Nuclear Proteins/metabolism , Trans-Activators/metabolism , Adaptor Proteins, Signal Transducing , Ataxia Telangiectasia Mutated Proteins/analysis , Cell Cycle Proteins , Cell Line , Histones/analysis , Histones/metabolism , Humans , Kinetochores/ultrastructure , Mitosis , Nuclear Proteins/analysis , Phosphorylation , Trans-Activators/analysisABSTRACT
Mouse mammary tumor virus (MMTV) is associated primarily with mammary carcinomas and lymphomas. The signal peptide of the MMTV envelope precursor is uniquely targeted to nucleoli of cells that harbor the virus, where it can function as a nuclear export factor for intron-containing transcripts. Antibodies to this signal peptide, which we refer to as p14, were previously shown to label nucleoli in a subset of human breast cancers. To look for additional cellular functions of p14, different mutants were ectopically expressed in the MCF-7 human breast cancer cell line. This approach identified motifs responsible for its nucleolar targeting, nucleocytoplasmic shuttling, target protein (B23, nucleophosmin) binding, and phosphorylation at serine 18 and 65 both in situ and in vitro. To test the role of these phosphorylation sites, we carried out in vivo tumorigenesis studies in severe combined immunodeficient mice. The findings show that the p14-Ser65Ala mutation is associated with impaired tumorigenicity, whereas the p14-Ser18Ala mutation is associated with enhanced tumorigenicity. Microarray analysis suggests that phosphorylation at serine 18 or at serine 65 is associated with transcriptional regulation of the L5 nucleolar ribosomal protein (a p14 target) and the Erb-B signal transduction pathway. Taken together, these results show that the phosphorylation status of p14 determines whether it functions as a pro-oncogenic or antioncogenic modulator.
Subject(s)
Mammary Neoplasms, Experimental , Mammary Tumor Virus, Mouse , Protein Sorting Signals/genetics , Viral Envelope Proteins , Animals , Cell Nucleolus/metabolism , Cell Nucleolus/virology , Cell Transformation, Neoplastic/genetics , Cell Transformation, Neoplastic/immunology , Female , Gene Expression Regulation, Neoplastic , Humans , MCF-7 Cells , Mammary Neoplasms, Experimental/metabolism , Mammary Neoplasms, Experimental/virology , Mammary Tumor Virus, Mouse/genetics , Mammary Tumor Virus, Mouse/metabolism , Mice , Mutation , Phosphoproteins/genetics , Phosphoproteins/metabolism , Phosphorylation , Ribosomal Proteins/genetics , Ribosomal Proteins/metabolism , Signal Transduction , Viral Envelope Proteins/genetics , Viral Envelope Proteins/metabolismABSTRACT
Chromosomal instability in early cancer stages is caused by stress on DNA replication. The molecular basis for replication perturbation in this context is currently unknown. We studied the replication dynamics in cells in which a regulator of S phase entry and cell proliferation, the Rb-E2F pathway, is aberrantly activated. Aberrant activation of this pathway by HPV-16 E6/E7 or cyclin E oncogenes significantly decreased the cellular nucleotide levels in the newly transformed cells. Exogenously supplied nucleosides rescued the replication stress and DNA damage and dramatically decreased oncogene-induced transformation. Increased transcription of nucleotide biosynthesis genes, mediated by expressing the transcription factor c-myc, increased the nucleotide pool and also rescued the replication-induced DNA damage. Our results suggest a model for early oncogenesis in which uncoordinated activation of factors regulating cell proliferation leads to insufficient nucleotides that fail to support normal replication and genome stability.
Subject(s)
Genomic Instability , Neoplasms/genetics , Nucleotides/biosynthesis , Cyclin E/metabolism , DNA Replication , E2F Transcription Factors/metabolism , Humans , Loss of Heterozygosity , Neoplasms/metabolism , Neoplasms/pathology , Nucleotides/metabolism , Oncogene Proteins, Viral/metabolism , Papillomavirus E7 Proteins/metabolism , Repressor Proteins/metabolism , Retinoblastoma Protein/metabolism , S PhaseABSTRACT
In addition to its nutritional value, cranberry juice has been effective in treating urinary tract infections. Various reports have also demonstrated its potential for inhibiting in vitro growth of transformed cell lines. Here we show that a fraction [nondialyzable material (NDM) of a molecular weight range 12,000-30,000 (NDM 12-30K)] derived from cranberry juice impairs in vitro growth and invasion through extracellular matrix of Rev-2-T-6 murine lymphoma cells. Furthermore, intraperitoneal injection of this fraction at nontoxic doses both inhibits the growth of Rev-2-T-6 tumors in vivo and enhances the generation of antilymphoma antibodies. These findings demonstrate the in vivo efficacy of cranberry components against malignant lymphoma in immune competent hosts.